Clinical trials: Prostate Cancer, Castration Resistant
Castration-Resistant Prostate Cancer (CRPC)
A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit.
- Trial name
- NCT01534052
- Testing
- Enzalutamide
- Where
- 7 sites in United States, Moldova and 1 more
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Inc
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones
This phase II trial studies the effect of Sn-117m-DTPA on bone pain in patients with prostate cancer that has spread to the bones. Sn-117m-DTPA is a radioactive therapeutic agent that localizes to bones when given to patients.
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT04616547
- Testing
- Questionnaire Administration, Tin Sn 117m Pentetate
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
This phase I trial studies side effects and best dose of PSCA-chimeric antigen receptor (CAR) T cells in treating patients with prostate stem cell antigen positive (PSCA+) castration resistant prostate cancer that has spread to…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT03873805
- Testing
- Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- City of Hope Medical Center
Metastatic Castration-resistant Prostate Cancer
Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)
This is a study of pembrolizumab (MK-3475) in participants with metastatic castration-resistant prostate cancer (mCRPC). Participants will be enrolled into one of five cohorts: Cohort 1 (participants with programmed cell death…
- Trial name
- NCT02787005
- Testing
- Pembrolizumab
- Volunteers
- 388 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
The purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer.
- Trial name
- NCT01171898
- Testing
- ARN-509 (Phase 1), ARN-509 (Phase 2)
- Where
- 15 sites in United States
- Volunteers
- 127 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer
This phase II trial studies how well pembrolizumab and HER2Bi-armed activated T cells work in treating patients with castration resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Progression
- Trial name
- NCT03406858
- Testing
- HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.
- Trial name
- CheckMate 9KD (NCT03338790)
- Testing
- nivolumab, docetaxel, enzalutamide
- Where
- 66 sites in United States, Argentina and 9 more
- Volunteers
- 292 people
- Sponsor
- Bristol-Myers Squibb
Prostatic Neoplasms
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and docetaxel in the treatment of Chinese men with metastatic castration-resistant prostate cancer (mCRPC) who have not…
- Trial name
- NCT04907227
- Testing
- Pembrolizumab, Docetaxel, Prednisone
- Where
- 20 sites in China
- Volunteers
- 81 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Castration Resistant Prostate Cancer
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant Prostate Cancer
- Trial name
- RAMP (NCT04179396)
- Testing
- Rucaparib, Enzalutamide, Abiraterone
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- pharmaand GmbH
Prostate Cancer, Castration Resistant Prostate Cancer
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
This study will evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease…
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
- Trial name
- COMET-1 (NCT01605227)
- Testing
- cabozantinib, prednisone
- Where
- 264 sites in United States, Australia and 12 more
- Volunteers
- 1,028 people
- Sponsor
- Exelixis
Metastatic Progressive Castration-resistant Prostate Cancer
Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide
This study is being conducted to determine the effect of enzalutamide on the androgen signaling pathway in correlation with the anti-tumor effects of enzalutamide to identify potential predictors of response or resistance to…
- Trial name
- NCT01091103
- Testing
- Enzalutamide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Pfizer
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
This phase I/II trial is studying the side effects of giving cixutumumab together with temsirolimus and to see how well it works in treating patients with metastatic prostate cancer.
- Conditions
- Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT01026623
- Testing
- Cixutumumab, Diagnostic Laboratory Biomarker Analysis, Temsirolimus
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Castration-resistant Prostate Cancer
A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to look for markers of how Ra-223 improves the lives of men with prostate cancer. This study makes use of Ra-223 in the standard FDA-approved way, but adds non-standard testing in an attempt to gain…
- Conditions
- Prostate Cancer, Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer Metastatic to Bone
- Trial name
- NCT02346526
- Testing
- Blood Tests, CT scan, FACBC PET/MRI in a subset of participants
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Prostatic Neoplasms, Castration-Resistant
A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
This Phase III, multicenter, randomized, open-label study will evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) in combination with enzalutamide compared with enzalutamide…
- Trial name
- IMbassador250 (NCT03016312)
- Testing
- Atezolizumab, Enzalutamide
- Where
- 158 sites in United States, Australia and 19 more
- Volunteers
- 759 people
- Sponsor
- Hoffmann-La Roche
Metastatic Castration-resistant Prostate Cancer
Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
This research study is evaluating a drug called enzalutamide in metastatic castration resistant prostate cancer. Enzalutamide is already FDA approved for metastatic castration resistant prostate cancer after treatment with…
- Trial name
- NCT01942837
- Testing
- Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 67 people
- Sponsor
- Dana-Farber Cancer Institute
Solid Tumors, Non-small Cell Lung Cancer
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive…
- Conditions
- Solid Tumors, Non-small Cell Lung Cancer, Castration Resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer
- Trial name
- NCT03473925
- Testing
- Navarixin, Pembrolizumab
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
Abiraterone Post Ketoconazole for Prostate Cancer
This is a phase II, open label, single center study to evaluate the efficacy of abiraterone acetate (CB7630) administered to patients with castrate resistant prostate cancer who have experienced disease progression on…
- Trial name
- NCT01199146
- Testing
- Abiraterone acetate
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- University of California, San Francisco
Prostate Cancer Non-Metastatic, Castration-Resistant
Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.
- Trial name
- ARAMIS (NCT02200614)
- Testing
- Darolutamide (Nubeqa, BAY1841788)
- Where
- 404 sites in United States, Argentina and 34 more
- Volunteers
- 1,509 people
- Sponsor
- Bayer
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients
This phase II trial evaluated the impact of giving docetaxel together with lycopene supplements in treating patients with hormone-resistant prostate cancer not previously treated with chemotherapy.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01882985
- Testing
- Docetaxel, Lycopene
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, Irvine
Prostate Cancer
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
This is a single institution, open label, phase II study in androgen-independent prostate cancer patients who are chemotherapy-naïve. Patients will receive Torisel® 25 mg weekly.
- Trial name
- NCT00919035
- Testing
- torisel
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Oncology Specialists, S.C.